NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only
 

An open randomized study comparing d4T plus ddI and nevirapine (QD) vs d4T plus ddI and nevirapine (BID) in antiretroviral naive chronic HIV-1 infected patients in very early stages (Spanish SCAN study).

Garcia F, Knobel H, Sambeat MA, Romeu J, Segura F, Aranda M, Dalmau D, Alonso MM, Gatell JM, Miro JM; Conference on Retroviruses and Opportunistic Infections.

Program Abstr 6th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 6th 1999 Chic Ill. 1999 Jan 31-Feb 4; 6th: 186 (abstract no. 628).

Miro JM

The objective was to assess the equivalence between two triple therapies consisting on stavudine twice daily (d4T) plus full doses of didanosine (ddI) and nevirapine (NVP) given either twice or once daily in asymptomatic antiretroviral naive HIV-1 infected patients with CD4+ T cell count 500 x 10(6)/L and viral load 5000 copies /ml. End point was proportion of patients below 200 copies/ml after 6 months of follow-up. Patients were randomly assigned to d4T plus ddI and NVP (QD) (N=33) or d4T plus ddI and NVP (BID) (N=34). After 24 weeks of follow-up the virological response was: (Table: see text) Over a 24 weeks period, plasma HIV RNA viremia levels changed (in the AUC analysis) a mean +/- SD of - 1.598 +/- 0.55 log10 in the d4T + ddI (QD) + NVP (QD) group and -1.698 +/- 0.55 log10 in the d4T + ddI (BID) + NVP (BID) group (p= 0.53). At 24 weeks of follow-up CD4+ lymphocytes increased a mean +/- SD of 148 +/- 300 in the d4T + ddI (QD) + NVP (QD) group and 102 +/- 191 in the d4T + ddI (BID) + NVP (BID) group (p= 0.6). In 6 out of 67 (9%) the treatment had to be changed due to side effects. At 24 weeks of follow-up, the efficacy of two triple therapies consisting on d4T twice daily plus full doses of ddI and NVP given either twice or once daily in asymptomatic antiretroviral naive HIV-1 infected patients in early stage was very high and almost identical in both study arm. Tolerance was also similar.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Anti-HIV Agents
  • Biomedical Research
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes
  • Didanosine
  • HIV
  • HIV Infections
  • HIV-1
  • Humans
  • Nevirapine
  • Stavudine
  • Viral Load
  • reverse transcriptase, Human immunodeficiency virus 1
Other ID:
  • 20711863
UI: 102195393

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov